F Paroni Sterbini

Institute of Microbiology, Università Cattolica del Sacro Cuore, Rome, Italy.

3 publications 2020 – 2021 ORCID

What does F Paroni Sterbini research?

F Paroni Sterbini studies how various medications and infections can alter the balance of bacteria in the stomach, known as the gastric microbiome. By using advanced machine learning methods, they analyze complex networks to understand how these bacterial changes affect overall stomach health. This research is crucial for developing better treatment strategies for patients suffering from gastrointestinal issues related to these factors.

Key findings

  • Long-term use of certain drugs significantly alters bacterial balance in the stomach, which can lead to digestive health issues.
  • Advanced machine learning techniques uncovered hidden patterns in bacterial behavior that traditional methods cannot detect, enhancing our understanding of the gastric microbiome.
  • Insights gained from this study can lead to improved treatment strategies for patients with gastric problems linked to medication or infections.

Frequently asked questions

Does Dr. Paroni Sterbini study gastric issues?
Yes, they focus on how medications and infections affect the bacteria in the stomach.
What methods does Dr. Paroni Sterbini use in their research?
They use advanced machine learning techniques to analyze complex interactions in the gastric microbiome.
Is Dr. Paroni Sterbini's work relevant to patients taking long-term medications?
Yes, their research aims to improve treatment outcomes for patients experience digestive issues due to medications.

Publications in plain English

Nonlinear machine learning pattern recognition and bacteria-metabolite multilayer network analysis of perturbed gastric microbiome.

2021

Nature communications

Durán C, Ciucci S, Palladini A, Ijaz UZ, Zippo AG +14 more

Plain English
This study looked at how long-term use of certain drugs and infections change the balance of bacteria in the stomach. Researchers found that using advanced analysis techniques revealed hidden patterns in bacterial behavior that traditional methods missed, helping to uncover how these bacteria and their associated metabolites interact when the stomach environment is disturbed. Understanding these changes is important because it can lead to better insights into gastric health and treatment strategies. Who this helps: This benefits patients with gastric issues related to medication or infections, as well as doctors working to improve treatment outcomes.

PubMed

Pediatric oropharyngeal microbiome: Mapping in chronic tonsillitis and tonsillar hypertrophy.

2020

International journal of pediatric otorhinolaryngology

Galli J, Calò L, Posteraro B, Rossi G, Sterbini FP +2 more

Plain English
This study examined the germs found in the tonsils of children who have chronic tonsillitis or enlarged tonsils due to Obstructive Sleep Apnea Syndrome (OSAS), comparing them to healthy kids. They found that children with chronic tonsillitis had higher levels of Proteobacteria, while those with OSAS had more Fusobacteria, and healthy children had a mix of other types including Firmicutes and Actinobacteria. Understanding the different bacteria in these conditions can help doctors find better ways to prevent and treat tonsil-related issues in children. Who this helps: This helps patients, especially children with chronic tonsillitis, tonsillar hypertrophy, or OSAS, as well as their doctors.

PubMed

Increasedabundance is associated with clinical improvement in patients receiving rifaximin treatment.

2020

Beneficial microbes

Ponziani FR, Scaldaferri F, De Siena M, Mangiola F, Matteo MV +8 more

Plain English
This study looked at how treatment with rifaximin, an antibiotic, affects the gut bacteria in patients with digestive disorders like ulcerative colitis and irritable bowel syndrome. It found that 40% of patients reported improvements in their symptoms after taking rifaximin, and those who improved showed a significant increase in certain beneficial gut bacteria. This matters because it indicates that changes in gut bacteria are linked to better health outcomes for patients undergoing this treatment. Who this helps: Patients with gastrointestinal diseases.

PubMed

Publication data sourced from PubMed . Plain-English summaries generated by AI. Not medical advice.